- Total planned investment is around 500
million USD over five years to raise manufacturing
capacity
- Continues long-term strategy of increasing capacity to respond
to growing industry demand and new market opportunities
- Cytiva hiring nearly 1,000 personnel in Austria, China, Singapore, Sweden, Switzerland, and the
United States
- New manufacturing lines, 24/7 shift patterns, and increased
automation will deliver additional manufacturing capacity
AMERSHAM, United Kingdom,
Sept. 13, 2020 /PRNewswire/ --
Cytiva, a global life sciences leader, is expanding its
manufacturing capacity and hiring personnel in key areas to support
the long-term growth of the biotechnology industry.
Emmanuel Ligner, President and
CEO, Cytiva, says: "We know from our customers that availability
and lead time are the most important considerations after quality.
Cytiva's long-term commitment is to deliver the best product,
at the right time, and support our customers with expertise.
The industry is growing rapidly, now even more due to
COVID-19. Accelerating this investment will reinforce these
commitments."
While the COVID-19 pandemic is increasing short-term demand, the
biotherapeutics industry was already predicted to grow by double
digits between now and 20251. Cytiva's global
product manufacturing and distribution network encompasses 13 sites
across Asia, the Americas, and
Europe. The investments, totaling
around 500 million USD, will respond
to in-region, for-region demand, bolster security of supply through
dual manufacturing, and increase overall global capacity in key
product areas.
Cytiva is investing in talent, too, hiring nearly 1,000 people
around the world. Ligner says: "We're acquiring talent in every
area of our business, from commercial to those on production lines,
in order to better serve customers for the long term."
Single-use technologies are used to manufacture 85%2
of the biologics currently in pre-commercial and clinical
manufacturing lines. As regulatory approvals occur, demand for
single-use products at manufacturing scale is expected to grow
substantially. Through additional equipment and infrastructure
at multiple sites, Cytiva's capacity to manufacture single-use
products will more than double.
In Asia-Pacific, single-use
capacity will triple through a partnership with one of the largest
healthcare technology suppliers in China, Wego, which is already producing
consumables for Cytiva's customers in the region.
Cell culture media production will increase thanks to new
manufacturing lines and cleanroom space in Logan, Utah, as well as additional shifts and
personnel. The Singapore and
Pasching, Austria locations are
increasing output through more personnel and additional work
shifts. This follows on from a tenfold increase in powdered cell
culture media production announced in May
2018.
The manufacturing capacity of Cytiva's MabSelect and Capto
chromatography product platforms has doubled, as part of a
70 million USD per year (2017 - 2022)
capacity gains and facility modernization program at its Uppsala,
Sweden site. Now, the plant is
fully automated with the latest technology to allow continuous
manufacturing. Other elements include the capacity extension of the
Sephadex resin, setting-up additional facilities for in-house
manufacturing, and the development of automation and digitalization
infrastructure.
Cytiva is also enabling the rapidly growing cell and gene
therapy market through an investment in a new facility in Grens,
Switzerland to manufacture
single-use kits for its Sepax and Sefia cell processing
systems.
Cytiva has a longstanding and comprehensive Security of Supply
program in place which enables manufacturing output to respond to
market demands while ensuring that operations and service
capabilities continue safely. For some product lines, part of the
solution is having multiple sites able to deliver to
customers.
Ligner says: "Dual manufacturing assures our customers that if
one location encounters capacity constraints, we have plenty
of back-up ready to activate."
About Cytiva
Cytiva is a global life sciences leader
with over 7,000 associates across 40 countries dedicated to
advancing and accelerating therapeutics. As a trusted partner to
customers that range in scale and scope, Cytiva brings speed,
efficiency, and capacity to research and manufacturing workflows,
enabling the development, manufacture, and delivery of
transformative medicines to patients.
1 BioPlan's 2020 Report and Survey of
Biopharmaceutical Manufacturing Capacity and Production, p 29
2 BioPlan's 2020 Report and Survey of Biopharmaceutical
Manufacturing Capacity and Production, p 58
Photo -
https://mma.prnewswire.com/media/1252653/Cytiva_Capacity_Expansion.jpg
Logo -
https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg